- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05214599
Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults' Subjects of Both Genders With Eosinophilic Esophagitis (EoE) (BESIDE)
February 28, 2024 updated by: Bazell Pharma AG
A Phase I/II, Multicenter, Double-blind, Parallel, Randomized Trial to Assess Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults Subjects of Both Genders With Eosinophilic Esophagitis (EoE)
A phase I/II, multicenter, double-blind, parallel, randomized trial to assess pharmacokinetics, efficacy, tolerability and safety of different budesonide oral gel doses in adults subjects of both genders with eosinophilic esophagitis (EoE)
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
36
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subjects able to read, understand and sign the Informed Consent Form (ICF) approved by Ethical Committee;
- Male and female subjects aged between 18 and 75 years old;
- Body weight between 60-100 kg;
- Body mass index (BMI) ≥ 18.5 and ≤ 29.9 kg/m2;
- Non-childbearing potential female subjects. Childbearing potential is defined as: post-menopausal women (defined as 12 months of amenorrhea or more), hysterectomized women, oophorectomized (bilateral) women and/or those who underwent tubal ligation;
- Female participants of childbearing potential who test negative for the pregnancy test on the day of administration of the first dose of the drug (Visit 1), as well as throughout the clinical trial;
- Female participants who practice adequate contraception or who abstain from all activities that could result in pregnancy for at least 28 days before administering the first dose of the drug (Visit 1);
- Female participants who agree to continue adequate contraception for 1 month after administration of the last dose of the investigational drug;
- Participants diagnosed with EoE, verified from a combination of symptoms compatible with EoE and histological finding greater than 15 eosinophils per high-power field in at least one esophageal mucosal biopsy;
- Participants unresponsive to stable dose of proton-pump inhibitor (PPI).
Exclusion Criteria:
- Subjects with a malignancy history within the last 5 years, except from successfully treated basal cell carcinoma;
- History of esophageal stenosis requiring dilation and/or stenosis at endoscopy not allowing to pass the endoscope;
- Subjects with a eosinophilic gastroenteritis diagnosis (presence of eosinophilic infiltrate in gastric antrum and duodenum);
- Subjects with a reflux esophagitis history;
- Subject with a previous serious asthma diagnosis;
- Subjects with a gastroesophageal tract disease that, at the investigator's discretion, is deemed as an obstacle to take part in the trial;
- People with chronic diseases on regular drugs that, in the investigator's opinion, may interfere with the trial;
- Medical conditions such as serious heart or lung diseases preventing the safe performance of endoscopy;
- Subjects with conditions known to be related to esophageal eosinophilia, including Crohn's disease, Churg-Strauss, achalasia and hypereosinophilic syndrome;
- Subjects who have been on oral, intranasal or systemic corticosteroid at least 15 days prior to trial start;
- Smoker of having quit smoking less than 6 months ago;
- Have a history of excessive alcohol intake for at least 6 months prior to trial start (intake of 5 or more alcoholic beverages in one day or 15 or more alcoholic beverages per week);
- Subjects having 5 or more cups of tea or coffee per day and who cannot abstain from them for the trial period;
- Be on CYP3A4 inhibitors, such as ketoconazole and grapefruit juice;
- Electrocardiogram (ECG) findings that, in the investigator's opinion, may jeopardize participation in the trial;
- History or presence of gastrointestinal or liver disease or other condition interfering with drug absorption, distribution, excretion or metabolism;
- Subjects with hypersensitivity or contraindication of using any formulation components;
- Subjects who have been part of trial protocols in the last 12 (twelve) months (CNS Resolution 251, dated August 7, 1997, item III, sub-item J);
- Have donated blood (> 500 mL) or undergone major surgery within the 3 months prior to the ICF signature date;
- Have been vaccinated for the 30 days prior to admission;
- Clinical evidence of infectious process potentially contributing for dysphagia (candidiasis, cytomegalovirus (CMV), herpes);
- Other dysphagia cause identified at endoscopy (peptic stenosis, web, ring, achalasia, esophageal neoplasm);
- Breastfeeding subjects, who plan to become pregnant or with a positive pregnancy test during the trial;
- Any medical condition or laboratory change that, in the investigator's opinion, may jeopardize participation in the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
Low dose
|
Twice daily regimen
|
Experimental: Group 2
Middle dose
|
Twice daily regimen
|
Experimental: Group 3
High dose
|
Twice daily regimen
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of Pharmacokinetic Profiles
Time Frame: First 24 hours after a single drug dose administration
|
Peak Plasma Concentration (Cmax)
|
First 24 hours after a single drug dose administration
|
Determination of Pharmacokinetic Profiles
Time Frame: First 24 hours after a single drug dose administration
|
Area under the plasma concentration versus time curve (AUC)
|
First 24 hours after a single drug dose administration
|
Determination of Pharmacokinetic Profiles
Time Frame: First 24 hours after a single drug dose administration
|
Half-life (T1/2)
|
First 24 hours after a single drug dose administration
|
Determination of Pharmacokinetic Profiles
Time Frame: First 24 hours after a single drug dose administration
|
Oral clearance (CL/F)
|
First 24 hours after a single drug dose administration
|
Proportion of subjects reaching a histological response
Time Frame: 8 weeks of treatment
|
≤ 6 eosinophils per high power field
|
8 weeks of treatment
|
Improvement in dysphagia symptoms consistent with the disease
Time Frame: 8 weeks of treatment
|
EAT (Eating Assessment Tool) -10 questionnaire
|
8 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of non-serious and serious adverse events rate
Time Frame: Through 8 weeks
|
Through 8 weeks
|
|
Quality of life assessment of subjects
Time Frame: Through 8 weeks
|
WHOQOL-bref questionnaire
|
Through 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
July 31, 2024
Primary Completion (Estimated)
April 30, 2025
Study Completion (Estimated)
April 30, 2025
Study Registration Dates
First Submitted
January 3, 2022
First Submitted That Met QC Criteria
January 13, 2022
First Posted (Actual)
January 28, 2022
Study Record Updates
Last Update Posted (Estimated)
February 29, 2024
Last Update Submitted That Met QC Criteria
February 28, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Hematologic Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Hypersensitivity
- Esophageal Diseases
- Leukocyte Disorders
- Eosinophilia
- Eosinophilic Esophagitis
- Esophagitis
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Budesonide
Other Study ID Numbers
- BAZ006-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
There is not a plan to make individual participant data (IPD) available
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eosinophilic Esophagitis
-
Children's Hospital Medical Center, CincinnatiNational Institute of Allergy and Infectious Diseases (NIAID); National Institute... and other collaboratorsCompletedEosinophilic Esophagitis (EoE) | Eosinophilic Gastrointestinal Disorders (EGIDs)United States
-
Federico II UniversityRecruitingEsophagitis, EosinophilicItaly
-
Ann & Robert H Lurie Children's Hospital of ChicagoRecruitingEosinophilic Gastroenteritis | Eosinophilic Esophagitis | Eosinophilic Colitis | Eosinophilic Gastrointestinal DiseaseUnited States
-
Children's Hospital of PhiladelphiaRecruitingEosinophilic Esophagitis (EoE)United States
-
Medical University of GrazRecruiting
-
AQILION ABCompletedEosinophilic Esophagitis (EoE)United Kingdom
-
Regeneron PharmaceuticalsSanofiActive, not recruitingEosinophilic Esophagitis (EoE)United States, Canada
-
ShireTakeda Development Center Americas, Inc.TerminatedEosinophilic Esophagitis (EoE)United States
-
ShireCompletedEosinophilic Esophagitis (EoE)United States
-
ShireCompleted
Clinical Trials on Budesonide Gel
-
West Penn Allegheny Health SystemCompleted
-
Glyciome, LLCBrigham and Women's Hospital; University of Puerto RicoCompletedSensory Perceptual Characteristics | User Acceptability of Gel Delivery SystemUnited States, Puerto Rico
-
Novan, Inc.CompletedAcne VulgarisDominican Republic, Honduras, Panama
-
Starpharma Pty LtdCompletedBacterial VaginosisUnited States
-
Starpharma Pty LtdCompletedRecurrent Bacterial Vaginosis (BV)
-
DermBiont, Inc.Active, not recruiting
-
Alcon ResearchCompleted
-
NFlection Therapeutics, Inc.CompletedNeurofibromatosis 1 | Cutaneous NeurofibromaUnited States
-
University of NebraskaCompleted
-
Topokine Therapeutics, Inc.SuspendedExcess Submental Fat ("Double Chin")